Myriad Genetics (MYGN) Total Current Liabilities (2010 - 2026)

Myriad Genetics has disclosed Total Current Liabilities across 17 years of filings, most recently posting $130.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 13.83% year-over-year to $130.2 million; the TTM figure through Mar 2026 stood at $130.2 million (down 13.83% YoY), while the FY2025 annual figure was $133.8 million, down 18.46% from the prior year.
• Total Current Liabilities eased to $130.2 million in Q1 2026, from $133.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for MYGN reached as high as $221.1 million in Q2 2023 and fell as low as $119.7 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $148.9 million (2024), against an average of $156.4 million.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 55.83% — and 2023, when it surged 84.71%.
• A 5-year view of Total Current Liabilities shows it stood at $137.2 million in 2022, then gained by 13.63% to $155.9 million in 2023, then rose by 5.26% to $164.1 million in 2024, then dropped by 18.46% to $133.8 million in 2025, then decreased by 2.69% to $130.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $130.2 million, $133.8 million, and $148.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.